This announcement is a separate document:
6-K: Blenrep (Belantamab Mafodotin) Combinations in Relapsed/Refractory Multiple Myeloma Accepted for Regulatory Review in Japan
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.